What's Happening?
Oligonucleotide therapy manufacturers are increasingly adopting new technologies to meet the growing demand for these therapies, particularly as they reach the clinical stage. According to Barrie Cassey, PhD, a former technical director at GSK, the industry
is moving towards more cost-effective and scalable production techniques, such as enzymatic ligation. Currently, most oligonucleotide drugs are produced using solid-phase techniques, but this method has limited global manufacturing capacity. With a significant portion of these therapies targeting large patient populations, the demand is expected to exceed current manufacturing capabilities. Cassey notes that if 70% of Phase III assets become commercial, the global demand could rise to six to seven tons, surpassing today's capacity. To address this, companies are investing in new manufacturing plants and techniques, with some already offering preclinical manufacturing solutions.
Why It's Important?
The shift towards more efficient manufacturing methods for oligonucleotide therapies is crucial as the demand for these drugs increases, particularly for large patient populations. This transition is significant for the pharmaceutical industry as it seeks to reduce production costs and increase accessibility to these therapies. The ability to produce oligonucleotide drugs at scale could lead to more affordable treatments for patients, especially those with rare diseases. Additionally, the investment in new manufacturing technologies reflects the industry's commitment to innovation and adaptation in response to market needs. This development could also stimulate economic growth within the biotech sector, as companies expand their production capabilities and explore new therapeutic applications.
What's Next?
As the industry continues to evolve, it is likely that more pharmaceutical companies will invest in advanced manufacturing technologies to keep pace with the rising demand for oligonucleotide therapies. The adoption of these new techniques could lead to increased competition among manufacturers, potentially driving further innovation and cost reductions. Regulatory bodies may also play a role in facilitating the transition to these new methods by providing guidance and support for the approval of novel manufacturing processes. In the long term, the successful implementation of these technologies could pave the way for the development of new oligonucleotide-based treatments, expanding the range of conditions that can be effectively targeted by these therapies.
